About us
- >
- About us >
- Information >
- Announcement
2022-10-18
The Phase III clinical trial of ENERGI-F703 diabetic foot ulcer topical gel, which was applied for in the US, has successfully completed the 30-day re
We are pleased to announce that on October 18, 2022, our company received notification from the Contract Research Organization (CRO) that our investigational new drug, ENERGI-F703 diabetic foot ulcer topical gel, has completed the 30-day review period for the Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). This milestone means that we have received approval to proceed with the human Phase III clinical trial in the United States.